John Paul Waymack – MD, ScD
Dr. Waymack is one of the founders of Kitov. He has served as the chairman of Kitovs board of directors and as Chief Medical Officer, in which capacity he has been responsible for its medical operations, since 2013. Dr. Waymack has over 20 years of experience in the biopharma field. Dr. Waymack is a former academic transplant surgeon and FDA Medical Officer, with over 20 years of experience in drug development as a consultant for major pharmaceutical companies, including Pfizer, Roche, Pharmacia, Warner Lambert and Searle. During his 10-year academic career, Dr. Waymack published over 100 scientific essays, mainly in the fields of prostaglandins and immunology. Dr. Waymack was also an Associate Professor of Surgery at the University of Texas Medical Branch and at the University of Medicine and Dentistry of New Jersey. Dr. Waymack serves as a member of the board of directors and board of advisors for various public and private healthcare corporations, including member of the board of advisors for the publicly-traded Moleculin Corporation.
Isaac Israel has served as Kitov's CEO and a member of the board since 2012. Mr. Israel was the founding CEO of BeeContact (formerly TASE: BCNT), from 2001 until 2007. Since 2008, Mr. Israel has served as owner and founding CEO of Uneri Capital, a consulting firm in the capital markets field that specializes in the healthcare sector. Mr. Israel also serves as a member of the board of directors of various public and private healthcare corporations, including chairman of the board of NextGen Biomed, which is traded on the TASE.
Simcha Rock – CPA, MBA
Simcha Rock has served as Kitov's Chief Financial Officer and a member of the board since 2013. Mr. Rock was a Private Equity Manager at Edmond de Rothschild Private Equity Management, a firm specializing in the management of venture capital and other private equity investments funds, from 2000 until 2011. In that capacity, he was responsible for all financial, legal and administrative matters for several investment funds. Prior to that, Mr. Rock held financial management positions at Intel Electronics, The Jerusalem College of Technology, and JC Technologies. Mr. Rock holds a BA from Yeshiva University and an MBA from Cleveland State University.
Ido Agmon - MBA
Ido Agmon has served as a member of Kitov’s board since 2016. Mr. Agmon is a Manager of Aviv New-Tech, a private investment fund that manages a portfolio of public Israeli and global biomed and technology companies. He also serves as an independent consultant, providing startups and technology-based ventures with strategic planning and fundraising advice. Previously, he served as the CEO of Meytav Technology Incubator, an Israeli-based accelerator for biotech, pharma and medtech ventures with over 20 portfolio companies. Mr. Agmon has also served as a board member for a number of biomed ventures. He was the Director of Business Development at the ATI incubator, a technology incubator specializing in biomed and cleantech projects, where he was responsible for deal-flow and project evaluation. Mr. Agmon holds a BA in Business Administration and Life Sciences from Tel Aviv University, and an MBA from The Hebrew University of Jerusalem.
Steven Steinberg - CPA
Steven Steinberg has served as a member of Kitov’s board since 2016. Mr. Steinberg is the Chief Financial Officer of Glide Talk, a technology company in the video messaging arena. He previously served as Vice President, Finance at ClientConnect, a subsidiary of Conduit. Mr. Steinberg has provided startups and mature organizations with advice in financial reporting, due diligence and business models. He also served as CFO of Answers Corporation, a NASDAQ-listed company. He has held a number of finance and CFO roles following a 10-year stint as an Audit Manager at Coopers & Lybrand (currently Price Waterhouse Coopers) in New York City. Mr. Steinberg holds a BA in Business Administration from Florida International University – School of Business Administration, and was granted a CPA license in New York State.
Arye Weber - M.A.
Arye Weber has served as a member of Kitov’s board since 2017. Since 2001, Mr. Weber has been the chairman of the board and sole shareholder of Scorpio Investments, a private holding company for various investments. Between 2006 and 2009, Mr. Weber was the CEO of Alonei Meitar, a TASE-listed real estate development company. Between 2004 and 2008, Mr. Weber was the chairman of the board of Inventec Investments, a TASE-listed real estate development company. Between 1989 and 2002, Mr. Weber was the Manager of the Securities & Investments sector at United Mizrachi Bank, and prior to 1989, he served in various securities and investments department roles at the bank. Mr. Weber serves as a member of the board of directors of various public and private corporations. In the past, he held director positions at the Tel Aviv Stock Exchange Clearing House (chairman), Bank Mizrachi Registration Company (chairman), Mashabim United Mizrachi Bank Offerings Company, Tel Aviv Stock Exchange, Maalot Israel Rating Agency, and Excellence Investment Management Company. Mr. Weber holds an MA in Economics and Business Studies from the University of Kharkov, USSR (presently Ukraine).
Revital Stern-Raf - CPA, MBA
Revital Stern-Raf has served as a member of Kitov’s board since 2017. Since 2013, Ms. Stern-Raff has been the Chief Financial Officer of several municipal development and community association units of Givatayim, Israel. Ms. Stern-Raff held comptroller and economist positions at Ilex Medical, a publicly-traded medical diagnostic equipment company (TASE: ILX), between 2006 and 2013. Prior to 2006, she held a number of other comptroller and public accounting positions. Ms. Stern-Raff also was an independent director at Real Imaging Holdings, a publicly-traded breast cancer diagnostics company (TASE: RIMG), between 2009 and 2012. Ms. Stern-Raff is a licensed CPA in Israel, and holds an MBA in Finance and BA in Business Administration – Information Technology and Finance from the Rishon Letzion College of Management in Israel.
Dr. Gil Ben-Menachem – MSc, MBA, PhD
Dr. Gil Ben-Menachem has served as Kitov's Vice President Business Development since 2016. Dr. Ben-Menachem has over 15 years of experience in the pharmaceutical, biotechnology, and venture capital industries. He most recently served as Head of Innovative Products at Dexcel Pharma, Israel’s second-largest pharmaceutical company. Dr. Ben-Menachem previously served as Director of Business Development at Teva Pharmaceutical Industries, where he was responsible for business development efforts in connection with partnering and acquisition deals for late-stage innovative drug candidates. Previous to that, he served as CEO of OphthaliX, a company that developed drugs in the ophthalmology space, and Director of Business Development at Paramount Biosciences, a New York-based merchant bank and biotechnology venture capital firm. Dr. Ben-Menachem received his PhD from the Hebrew University, and MBA from the University of Maryland. He concluded his postdoctoral training in immunology and microbiology at the NIH.
Ran Tzror - CPA, MBA
Ran Tzror has served as a member of Kitov’s board since 2017. Since 2014, Mr. Tzror has been the director of S.Y. Glilot, a real-estate company. Between 2010 and 2014, he was employed by Teva Pharmaceutical Industries in various roles in corporate business development and the office of the CEO & President, and as Director of the Corporate Post Merger Integration Office. He was a senior associate at Somekh Chaikin Certified Public Accountants (Israel), a member firm of KPMG International, between 2007 and 2010. He was a legal intern at the commercial division of Yigal Arnon & Co., Advocates & Notary in 2006-2007. Mr. Tzror holds a BA in Accounting, LLB in Law, and MBA in Financial Management from Tel Aviv University. He also completed courses at the Kellogg Graduate School of Management at Northwestern University. Mr. Tzror was granted a CPA license in the State of Israel, and was also admitted as a member of the Israeli Bar Association.